Primary hyperammonaemia: Current diagnostic and therapeutic strategies
- PMID: 33179600
- PMCID: PMC8518097
- DOI: 10.34763/jmotherandchild.20202402si.2015.000006
Primary hyperammonaemia: Current diagnostic and therapeutic strategies
Abstract
Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any of the six enzymes or two transporters that are directly involved in the urea cycle function.The clinical situation is variable and largely depends on the time of onset. Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death. Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal. Early identification of patients is extremely important to start effective treatment modalities immediately. The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers. Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers.The reader will find here a brief overview describing the most relevant aspects of the clinical management of UCDs in an attempt to raise awareness for this important group of rare diseases.
Keywords: encephalopathy; haemodialysis; hyperammonaemia; low-protein diet; nitrogen metabolism; nitrogen scavengers; urea cycle.
Conflict of interest statement
None.
Figures

Similar articles
-
Hyperammonemia in urea cycle disorders: A toxic metabolite for the brain.Pediatr Int. 2025 Jan-Dec;67(1):e70121. doi: 10.1111/ped.70121. Pediatr Int. 2025. PMID: 40464331 Review.
-
Efficacy of peritoneal dialysis in neonates presenting with hyperammonaemia due to urea cycle defects and organic acidaemia.Nephrology (Carlton). 2019 Mar;24(3):330-335. doi: 10.1111/nep.13224. Nephrology (Carlton). 2019. PMID: 29356227
-
Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders.Pediatr Clin North Am. 2018 Apr;65(2):231-246. doi: 10.1016/j.pcl.2017.11.004. Epub 2018 Feb 2. Pediatr Clin North Am. 2018. PMID: 29502911 Review.
-
The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders.J Inherit Metab Dis. 2018 Jul;41(4):689-698. doi: 10.1007/s10545-018-0157-4. Epub 2018 Mar 8. J Inherit Metab Dis. 2018. PMID: 29520739
-
Severe hyperammonaemia in adults not explained by liver disease.Ann Clin Biochem. 2012 May;49(Pt 3):214-28. doi: 10.1258/acb.2011.011206. Epub 2012 Feb 20. Ann Clin Biochem. 2012. PMID: 22349554 Review.
Cited by
-
The Application of Neurodiagnostic Studies to Inform the Acute Management of a Newborn Presenting With Sarbamoyl Shosphate Synthetase 1 Deficiency.Child Neurol Open. 2021 Jan 22;8:2329048X20985179. doi: 10.1177/2329048X20985179. eCollection 2021 Jan-Dec. Child Neurol Open. 2021. PMID: 33644249 Free PMC article.
-
Hyperammonemia and inborn errors of metabolism.Transl Pediatr. 2024 Feb 29;13(2):200-202. doi: 10.21037/tp-23-593. Epub 2024 Feb 26. Transl Pediatr. 2024. PMID: 38455740 Free PMC article. No abstract available.
-
Valproate-induced hyperammonemic encephalopathy: the role of clinical pharmacists in medication safety-a case report.J Med Case Rep. 2025 Jul 1;19(1):302. doi: 10.1186/s13256-025-05294-z. J Med Case Rep. 2025. PMID: 40598597 Free PMC article.
-
Challenges in the diagnosis and management of urea cycle disorders in Romanian children.Med Pharm Rep. 2021 Aug;94(Suppl No 1):S36-S39. doi: 10.15386/mpr-2226. Epub 2021 Aug 10. Med Pharm Rep. 2021. PMID: 34527907 Free PMC article.
-
Gene Therapy in Combination with Nitrogen Scavenger Pretreatment Corrects Biochemical and Behavioral Abnormalities of Infant Citrullinemia Type 1 Mice.Int J Mol Sci. 2022 Nov 29;23(23):14940. doi: 10.3390/ijms232314940. Int J Mol Sci. 2022. PMID: 36499263 Free PMC article.
References
-
- Häberle J, Rubio V. Saudubray J-M, Baumgartner MR, Walter JH. Inborn metabolic diseases: diagnosis and treatment. 6th ed. Berlin, Heidelberg: Springer; 2016. Disorders of the urea cycle and related enzymes; pp. 295–308.pp. 658
-
- Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea cycle disorders overview. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. Genetic counseling, editors. GeneReviews® [Internet] Seattle, WA: University of Washington;; 2003. 1993–2020. Apr 29 [updated 2017 Jun 22] ISSN 2372-0697.
-
- Tuchman M. The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency. J Lab Clin Med. 1992;120(6):836–50. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical